TNF Pharmaceuticals (TNFA) 10-Q2018 Q3 Quarterly report

Filed: 14 Nov 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: admission, advisor, AIM, alter, amicable, analog, beneficially, bid, Broker, Catalyzed, cease, CEO, Certificate, choice, comment, Configuration, Connecticut, customary, death, declared, deployment, disability, disagreement, docket, effectuated, Enzymatic, equivalent, evidenced, exhaled, exploration, explore, FCS, fill, filling, finnCap, formal, fractional, fuchsin, fundamental, gave, hereunder, holder, Howard, immunoassay, instrument, issuable, Joshua, London, lump, metabisulfite, Micro, Minnesota, obsolescence, occurrence, Particle, preformed, pulled, rapidly, ratio, removal, repurchased, seminar, shelf, Silverman, simultaneously, sodium, split, substance, surviving, System, television, thereof, uniformly, voluntary, write, wrongdoing, Yeaton

Removed: achieve, affordable, agent, assemble, British, cancellation, chlamydia, clearance, conducted, disease, enter, environment, establishing, evaluated, evolving, FDA, Free, generate, KetoChek, marketed, metabolic, novotek, pipeline, Poland, Pound, Radical, seraSTAT, strength, underway, utilize

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

TNFA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Akers Biosciences, Inc. (the “Company”), on Form 10-Q for the period ended September 30, 2018, as filed with the U.S. Securities and Exchange Commission on the date hereof, the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: November 14, 2018	By:	/s/ Howard Yeaton
		Howard Yeaton
		Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
		Akers Biosciences, Inc.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.